Munich - Delayed Quote EUR

Advicenne SA (3MM.MU)

1.8080

+0.1600

(+9.71%)

At close: December 23 at 8:18:24 AM GMT+1

Advicenne Announces its 2025 Financial Calendar

PARIS, November 28, 2024--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2025 financial communication calendar.

Business Wire 27 days ago

ALDVI.PA
FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria.

PARIS, March 25, 2024--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced that its proprietary drug ADV7103 has been granted Orphan Drug Designation (ODD) status for the treatment of cystinuria. This designation was issued by the US Food and Drug Administration (US FDA). ADV7103 is one of the few drugs t

Business Wire 8 months ago

ALDVI.PA

Performance Overview

Return	3MM.MU	CAC 40
YTD	-30.99%	-3.45%
1-Year	-22.07%	-3.78%
3-Year	-75.23%	+2.48%